In May'20 MolPort's successful partnership with BioAscent has announced the successful completion of 100 projects. Through collaborative efforts, both companies significantly enhanced customer service by providing compounds in consistent formats and times, reducing variability, and simplifying the sourcing challenge for scientists world-wide.
The partnership, established in 2016, combines MolPort's online compound procurement platform - consisting of multiple high-quality compound suppliers, detailed product information, and its project management capabilities - with BioAscent's expert team of scientists that provide on-demand, automated, quality-controlled compound dissolution and customised reformatting services. MolPort receives many samples from suppliers in multiple formats, including solids, dry film, and solution in vials or multi-well plates. In partnering with BioAscent, deliveries are custom-designed so that customers receive all compounds in their specified, ready-to-use formats and layouts. Receiving these compounds without any specification uncertainties means scientists spend less time on the logistics of compound searching and ordering prior to research - considerably improving laboratory efficiency.
Reaching the 100-project milestone meant successfully fulfilling a diverse range of customer requests. Ranging from large to relatively small project sizes, different levels of project complexity and various timeframes, MolPort and BioAscent tailored their support to suit the needs of the customer.
In one of the partnership's largest collaborative projects, both companies competently delivered a sizeable order of 143,531 compounds from 17 different suppliers, having managed all supplier communications, compound reformatting and project logistics. This was all carried out within eight weeks - from initial idea to purchase a compound library to sending the compounds to BioAscent for reformatting and management. The customer required just one single point of contact and the collaboration ensured products were delivered on-time so that screenings were carried out as scheduled. See all case studies.
BioAscent's Chief Operating Officer, Sylviane Boucharens, added: "We value our highly successful relationship with MolPort and are delighted to have reached this key milestone. Together we can provide an end-to-end service which includes compound searching, sourcing, acquisition, custom formatting, delivery and secure storage. This collaboration makes good use of BioAscent's state-of-the-art compound management, automated liquid handling, plating, QC and distribution capabilities. With our IT capabilities, we are able to ensure all samples and compound handling and plating activities are fully trackable and auditable."
"We are extremely pleased to complete our 100th project with our drug development services partner, BioAscent, helping customers address their compound supply and logistics challenges", said Imants Zudans, CEO at MolPort. "Our long-term collaboration helps customers select the most reliable and cost-effective suppliers, enjoy on-time and on-budget delivery of complete compound libraries, and receive samples formatted to their exact and complex requirements - ready for immediate screening. Our work removes administrative overhead, saving customers time and money, so that they can focus all their attention on the actual science itself."
MolPort covers many aspects of ordering, including access to commercially available compound data, customer communication and compound acquisition. Customers can choose from over 7.6 million compounds from major suppliers using MolPort's comprehensive database with continuously updated compound information, such as solubility data, to guide customers into choosing the right compounds for their research. The importance of providing solubility data was highlighted while working closely with customers who stated that a lack of compound solubility information can create challenges for the pharmaceutical industry, especially during compound screening.
The MolPort and BioAscent collaboration makes the lead discovery process considerably more efficient and less complex for any laboratories performing compound screenings. This partnership benefits not only biopharmaceutical companies, but also research institutions, universities, and biotech companies around the world.